Answers are grounded in this paper and cite their sources.
Background. Green pit viper (Trimeresurus spp.) envenomation can cause venom-induced consumptive coagulopathy (VICC), for which species-specific antivenom is the cornerstone of therapy. The standard Indonesian trivalent antivenom does not cover Trimeresurus. This report aims to describe the presentation, antivenom dosing, and hematologic recovery of a child with severe VICC after a green pit viper bite and ineffective trivalent antivenom. Case. A 3-year-old boy (15 kg) was referred to a tertiary hospital three days after a finger bite, with swelling of the entire right arm. At a district hospital, coagulation was initially normal (PT 13.1 s, platelets 440,000/µL), and trivalent antivenom produced no improvement. Findings. On referral (Day 0), PT and APTT exceeded 180 s, INR was unmeasurable, and platelets were 6,000/µL. A green snake with a red tail was described, and green pit viper envenomation was diagnosed clinically. Because of limited stock, he received two vials of monovalent green pit viper antivenom on Day 0 (platelets 10,000/µL on Day 1), followed by three vials on Day 1. By Day 2, platelets were 63,000/µL, PT 10.7 s, APTT 15.8 s, and INR 0.99; platelets reached 163,000/µL on Day 4. No transfusion or antivenom reaction occurred, and he was discharged on Day 10. Conclusion. Coagulopathy resolved after species-specific antivenom despite a 72-hour delay, whereas non-specific antivenom had no apparent effect. This case supports antivenom selection guided by clinical toxinology, adult-equivalent vial dosing in children, and repeat coagulation testing, particularly in resource-limited settings.
No takes yet. Share an insight, caveat, or question.
Mustafa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: